Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3755MR)

This product GTTS-WQ3755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5405MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ5294MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ4829MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ14355MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ15830MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ1817MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1467MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ5552MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7657
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW